Northern Trust’s Ocera Therapeutics, Inc. OCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-15,883
| Closed | -$18K | – | 4295 |
|
|
2017
Q3 | $18K | Hold |
15,883
| – | – | ﹤0.01% | 4166 |
|
|
2017
Q2 | $18K | Hold |
15,883
| – | – | ﹤0.01% | 4188 |
|
|
2017
Q1 | $21K | Buy |
15,883
+2,565
| +19% | +$3.27K | ﹤0.01% | 4151 |
|
|
2016
Q4 | $28K | Buy |
13,318
+532
| +4% | +$1.24K | ﹤0.01% | 4074 |
|
|
2016
Q3 | $34K | Hold |
12,786
| – | – | ﹤0.01% | 4062 |
|
|
2016
Q2 | $24K | Sell |
12,786
-400
| -3% | -$1.05K | ﹤0.01% | 4100 |
|
|
2016
Q1 | $39K | Buy |
13,186
+400
| +3% | +$1.14K | ﹤0.01% | 4057 |
|
|
2015
Q4 | $40K | Hold |
12,786
| – | – | ﹤0.01% | 4087 |
|
|
2015
Q3 | $40K | Buy |
+12,786
| New | +$49.2K | ﹤0.01% | 4114 |
|
|
2015
Q2 | – | Sell |
-10,833
| Closed | -$51K | – | 4311 |
|
|
2015
Q1 | $51K | Hold |
10,833
| – | – | ﹤0.01% | 4150 |
|
|
2014
Q4 | $69K | Buy |
+10,833
| New | +$63.4K | ﹤0.01% | 4053 |
|
|
2013
Q3 | – | Sell |
-3,527
| Closed | -$20K | – | 4129 |
|
|
2013
Q2 | $20K | Buy |
+3,527
| New | +$21.9K | ﹤0.01% | 4001 |
|
Northern Trust's OCRX Position: Q4 2017 in Review
Northern Trust sold out of Ocera Therapeutics, Inc. (OCRX) in Q4 2017, closing a stake of 15,883 shares — an estimated $18K sold.
Northern Trust first reported a position in OCRX in Q2 2013 and held it in 12 quarters. The position peaked at $69K in Q4 2014. 0 funds tracked by Wall St. Rank hold OCRX as of Q4 2017.
- Northern Trust reported no remaining Ocera Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
- Northern Trust sold 15,883 Ocera Therapeutics, Inc. shares in Q4 2017, an estimated $18K.
- Northern Trust first reported a position in Ocera Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
- Northern Trust's Ocera Therapeutics, Inc. position peaked at $69K in Q4 2014.
- 0 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q4 2017.
Based on Northern Trust's 13F filing for Q4 2017, filed 14 Feb 2018.